Biohaven Ltd. $BHVN Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC grew its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 291.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 105,518 shares of the company’s stock after acquiring an additional 78,585 shares during the quarter. SG Americas Securities LLC’s holdings in Biohaven were worth $1,191,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd lifted its holdings in shares of Biohaven by 834.4% in the third quarter. Qube Research & Technologies Ltd now owns 1,265,597 shares of the company’s stock valued at $18,997,000 after buying an additional 1,130,157 shares during the period. Norges Bank acquired a new stake in shares of Biohaven in the second quarter valued at $12,735,000. Bellevue Group AG lifted its holdings in shares of Biohaven by 37.3% in the second quarter. Bellevue Group AG now owns 2,802,853 shares of the company’s stock valued at $39,548,000 after buying an additional 762,000 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Biohaven by 986.0% in the third quarter. Two Sigma Investments LP now owns 799,600 shares of the company’s stock valued at $12,002,000 after buying an additional 725,969 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Biohaven in the second quarter valued at $9,289,000. Institutional investors and hedge funds own 88.78% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on BHVN shares. Leerink Partners restated an “outperform” rating and issued a $15.00 price objective on shares of Biohaven in a report on Tuesday, March 3rd. William Blair restated a “market perform” rating on shares of Biohaven in a report on Friday, December 26th. Citigroup upped their price objective on Biohaven from $14.00 to $17.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Morgan Stanley cut their price objective on Biohaven from $26.00 to $21.00 and set an “overweight” rating for the company in a report on Tuesday, January 6th. Finally, The Goldman Sachs Group raised Biohaven to a “strong-buy” rating in a report on Friday, February 6th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $22.64.

Biohaven Trading Up 1.4%

Shares of NYSE BHVN opened at $9.28 on Wednesday. Biohaven Ltd. has a 12 month low of $7.48 and a 12 month high of $24.06. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -1.33 and a beta of 1.34. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of 4.59. The business has a fifty day simple moving average of $10.48 and a 200-day simple moving average of $11.70.

Biohaven (NYSE:BHVN) last announced its earnings results on Monday, March 2nd. The company reported ($1.21) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.01. Sell-side analysts predict that Biohaven Ltd. will post -8.9 EPS for the current year.

Biohaven Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.